Summary
Glenmark Pharmaceuticals to launch Brukinsa (zanubrutinib) in India after DCGI approval, offering treatment for five B-cell blood cancers with fewer cardiac side effects and flexible dosing options.
Source: The Financial Express
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
